307 related articles for article (PubMed ID: 21499090)
1. Are statins diabetogenic?
Sampson UK; Linton MF; Fazio S
Curr Opin Cardiol; 2011 Jul; 26(4):342-7. PubMed ID: 21499090
[TBL] [Abstract][Full Text] [Related]
2. Statin-associated incident diabetes: a literature review.
Park ZH; Juska A; Dyakov D; Patel RV
Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
[TBL] [Abstract][Full Text] [Related]
4. Diabetogenic Action of Statins: Mechanisms.
Carmena R; Betteridge DJ
Curr Atheroscler Rep; 2019 Apr; 21(6):23. PubMed ID: 31037345
[TBL] [Abstract][Full Text] [Related]
5. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
6. Statin-Associated Diabetes Mellitus: Review and Clinical Guide.
Backes JM; Kostoff MD; Gibson CA; Ruisinger JF
South Med J; 2016 Mar; 109(3):167-73. PubMed ID: 26954655
[TBL] [Abstract][Full Text] [Related]
7. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
[TBL] [Abstract][Full Text] [Related]
8. Diabetes Secondary to Treatment with Statins.
Laakso M; Kuusisto J
Curr Diab Rep; 2017 Feb; 17(2):10. PubMed ID: 28155189
[TBL] [Abstract][Full Text] [Related]
9. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
Mora S; Glynn RJ; Hsia J; MacFadyen JG; Genest J; Ridker PM
Circulation; 2010 Mar; 121(9):1069-77. PubMed ID: 20176986
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.
Ridker PM; Pradhan A; MacFadyen JG; Libby P; Glynn RJ
Lancet; 2012 Aug; 380(9841):565-71. PubMed ID: 22883507
[TBL] [Abstract][Full Text] [Related]
11. Statins are diabetogenic--myth or reality?
Sattar N; Taskinen MR
Atheroscler Suppl; 2012 Aug; 13(1):1-10. PubMed ID: 22818818
[TBL] [Abstract][Full Text] [Related]
12. Is diabetes the cost to pay for a greater cardiovascular prevention?
Rizzo M; Spinas GA; Rini GB; Berneis K
Int J Cardiol; 2010 Oct; 144(2):309-10. PubMed ID: 19297038
[TBL] [Abstract][Full Text] [Related]
13. New onset diabetes mellitus induced by statins: current evidence.
Chrysant SG
Postgrad Med; 2017 May; 129(4):430-435. PubMed ID: 28276790
[TBL] [Abstract][Full Text] [Related]
14. Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Khan SU; Rahman H; Okunrintemi V; Riaz H; Khan MS; Sattur S; Kaluski E; Lincoff AM; Martin SS; Blaha MJ
J Am Heart Assoc; 2019 Apr; 8(7):e011581. PubMed ID: 30898075
[TBL] [Abstract][Full Text] [Related]
15. Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis.
Cui JY; Zhou RR; Han S; Wang TS; Wang LQ; Xie XH
J Clin Pharm Ther; 2018 Aug; 43(4):556-570. PubMed ID: 29733433
[TBL] [Abstract][Full Text] [Related]
16. [STATINS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE AND DIABETES INCIDENCE--THE BENEFITS VERSUS THE RISKS].
Lavie G; Cohen S
Harefuah; 2015 Jun; 154(6):382-6, 404. PubMed ID: 26281083
[TBL] [Abstract][Full Text] [Related]
17. Use of Statins and the Risk of Incident Diabetes: A Retrospective Cohort Study.
Olotu BS; Shepherd MD; Novak S; Lawson KA; Wilson JP; Richards KM; Rasu RS
Am J Cardiovasc Drugs; 2016 Oct; 16(5):377-90. PubMed ID: 27272032
[TBL] [Abstract][Full Text] [Related]
18. Statin use and risk of new-onset diabetes: A meta-analysis of observational studies.
Casula M; Mozzanica F; Scotti L; Tragni E; Pirillo A; Corrao G; Catapano AL
Nutr Metab Cardiovasc Dis; 2017 May; 27(5):396-406. PubMed ID: 28416099
[TBL] [Abstract][Full Text] [Related]
19. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
[TBL] [Abstract][Full Text] [Related]
20. Do statins really cause diabetes? A meta-analysis of major randomized controlled clinical trials.
Rahal AJ; ElMallah AI; Poushuju RJ; Itani R
Saudi Med J; 2016 Oct; 37(10):1051-60. PubMed ID: 27652354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
